Halozyme Therapeutics HALO Debt issuance costs and discount amortization
Debt issuance costs and discount amortization at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's debt issuance costs and discount amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's debt issuance costs and discount amortization?
- Halozyme Therapeutics (HALO) reported debt issuance costs and discount amortization of $2.25M in Q1 2026.
- How has Halozyme Therapeutics's debt issuance costs and discount amortization changed year-over-year?
- Halozyme Therapeutics's debt issuance costs and discount amortization increased by 21.6% year-over-year, from $1.85M to $2.25M.
- What is the long-term trend for Halozyme Therapeutics's debt issuance costs and discount amortization?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's debt issuance costs and discount amortization has grown at a 19.8% compound annual growth rate (CAGR), from $3.64M to $7.51M.
- What does debt issuance costs and discount amortization mean?
- This reflects the non-cash amortization of debt issuance costs or original issue discounts associated with corporate borrowings. It is added back to net income as it represents a non-cash adjustment to interest expense.